XGX Pharma ApS: Financial statements 2016
CVR: 32289290
Source: annual report 2016, Danish Business Authority
01/01/2016 – 31/12/2016
XGX Pharma ApS (CVR 32289290) has filed annual accounts for 2016. In 2016, the company reported a gross profit of DKK 307,092 and a net result of DKK 271,902 compared with DKK -34,858 the year before. Equity in the 2016 report amounted to DKK 92,180. The solvency ratio was 10.5%.
- Gross Profit
- DKK 307,092
- Profit/Loss
- DKK 271,902
- Equity
- DKK 92,180
- Total Assets
- DKK 876,843
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2016 | - | 307 t. | 272 t. | 92 t. | - |
| 2015 | - | -33 t. | -35 t. | -180 t. | - |
| 2014 | - | - | -14 t. | -145 t. | - |
| 2013 | - | 145 t. | 145 t. | 130 t. | - |
| 2012 | - | 84 t. | 96 t. | -14 t. | - |
Official annual report
Find more companies like XGX Pharma ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2016
XGX Pharma ApS has published its annual report for 2015. Gross profit came to DKK -32,643, and the net result was DKK -34,858.
About XGX Pharma ApS
XGX Pharma ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Jens-Nikolaj Schøier. The board consists of Per Anders Larnholt (chair) and Johan Frödin. The company is owned by Unimedic Pharma AB. The company has 2 employees (2018). In 2025, the company reported a gross profit of DKK 32,338,381 and a net result of DKK 16,074,119 compared with DKK 4,453,433 the year before. Equity in the 2025 report amounted to DKK 30,787,180.